-
AR Heterogeneity and Enzalutamide Response in CRPC
2026-08-30
Li and colleagues show that androgen receptor heterogeneity is a functional determinant of castration and enzalutamide response in prostate cancer, rather than merely a pathological feature. Their integrated tissue, xenograft, genome-editing, transcriptomic, and pharmacological analyses identify AR-low or AR-negative populations as a distinct resistant state and support BCL-2 targeting as a complementary strategy.
-
Balsalazide Disodium: Designing Better IBD Assays
2026-08-29
Balsalazide disodium is a colon-targeted 5-aminosalicylic acid prodrug with unusual implications for assay design. This guide connects bacterial activation, formulation variables, translational dosing, and rigorous controls for inflammation research and inflammatory bowel disease models.
-
Five-Element Nanoparticles for Stable Lung mRNA Delivery
2026-08-28
Cao and colleagues developed five-element nanoparticles (FNPs) that combine poly(β-amino esters) with DOTAP to improve lung-selective mRNA delivery and formulation stability. Their structure–activity analysis and lyophilization results indicate that polymer end-cap chemistry, polymerization degree, and alkyl-chain length can influence performance, while selected formulations remained stable after storage at 4 °C.
-
JC-1 as a Mechanistic Readout of Mitochondrial Stress
2026-08-28
JC-1 converts mitochondrial membrane potential into a ratiometric fluorescence signal. This guide connects JC-1 assay interpretation with the DRP1-linked mitochondrial mechanism reported in anaplastic thyroid cancer, helping researchers distinguish functional readouts from causal claims.
-
SIA-cIgG–PTPN13 Drives HNSCC Chemoresistance
2026-08-27
The reference study identifies a SIA-cIgG/PTPN13 signaling axis that links tumor stemness with poor chemotherapy response in head and neck squamous cell carcinoma. Using cell models, xenografts, and patient-derived organoids, the authors show that anti-SIA-cIgG combinations can improve responses to standard drugs, including Cisplatin, while addressing interpatient treatment heterogeneity.
-
Losartan Hydrogel Reprograms Tumor Mechanics
2026-08-27
Hou and colleagues developed LOS&FeOX@Gel, an in situ nanocomposite hydrogel that combines Losartan with oxaliplatin to remodel the stiff, matrix-rich environment of post-chemotherapy tumors. The study shows that reducing extracellular-matrix deposition and solid stress can improve chemotherapy activity and restore sensitivity to checkpoint blockade in preclinical models.
-
Structure-Guided Proteomimetics for SARS-CoV-2 Entry
2026-08-26
This study converts key human ACE2 recognition elements into constrained proteomimetics that target the large, shallow SARS-CoV-2 Spike receptor-binding interface. The linked construct selectively disrupted S-RBD–hACE2 binding, inhibited pseudovirus entry, and showed stability and permeability properties relevant to possible local antiviral delivery.
-
Escitalopram Workflows for Antidepressant Research
2026-08-26
Use Escitalopram as a selective serotonergic benchmark for transporter assays, dose-response studies, and translational antidepressant research. A workflow built around matched vehicle controls, orthogonal readouts, and phenotype-aware endpoints helps distinguish 5-HT reuptake inhibition from broader behavioral or augmentation effects.
-
Carvacrol and Redox-Gated TRP Assays
2026-08-25
Carvacrol research is advancing from broad bioactivity screening toward mechanism-aware assay design. This article explains how TRPV1/TRPA1 redox sensing can refine cell cycle research, apoptosis research, and interpretation of oxidative-stress experiments.
-
Triacetin: From Metabolism to Translational Strategy
2026-08-25
Triacetin, or glyceryl triacetate, is more than a formulation excipient: it is a defined short-chain triacylglycerol that connects acetate metabolism, AMPK signaling, epigenetic regulation, and experimental cancer biology. This thought-leadership analysis separates established observations from translational hypotheses and outlines how researchers can use Triacetin to build more rigorous metabolic, glioblastoma, and ocular workflows.
-
CCG-1423: From RhoA Signaling to Translational Insight
2026-08-24
CCG-1423 offers a mechanistically distinct way to interrogate RhoA-driven transcription through MRTF-A nuclear import. This article connects cancer biology with emerging viral-pathogenesis evidence while defining practical validation strategies and translational limits.
-
Measuring Drug Response Beyond Relative Viability
2026-08-24
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing why growth inhibition and cell killing should not be treated as interchangeable outcomes in cancer drug studies. The framework supports more interpretable in vitro experiments by incorporating response magnitude, timing, and orthogonal evidence of cell death.
-
Probenecid Workflows for Transport and Tumor Studies
2026-08-23
Probenecid supports controlled studies of MRP-mediated drug efflux, pannexin-1 signaling, and ischemia-associated neural injury. This practical guide connects transporter pharmacology with CD8+ T-cell immunometabolism while separating established evidence from hypothesis-generating assay extensions.
-
Recombinant Mouse M-CSF: Macrophage Workflows
2026-08-22
Build more consistent macrophage differentiation, metabolic profiling, and fibrosis-relevant assays with a defined mouse cytokine input. This practical guide shows how to use M-CSF without a tag while controlling dose, timing, phenotype drift, and assay variability.
-
Machine Learning Discovery of Senolytics
2026-08-22
The reference study shows that machine learning trained only on published screening data can identify senolytic candidates despite small and heterogeneous datasets. Computational screening followed by human-cell validation highlighted ginkgetin, periplocin, and oleandrin, providing a lower-cost framework for early-stage senolytic discovery.